ProfileGDS5678 / 1458181_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 35% 32% 33% 34% 35% 33% 32% 34% 34% 32% 34% 34% 33% 32% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8300235
GSM967853U87-EV human glioblastoma xenograft - Control 22.730332
GSM967854U87-EV human glioblastoma xenograft - Control 32.7539233
GSM967855U87-EV human glioblastoma xenograft - Control 42.7285534
GSM967856U87-EV human glioblastoma xenograft - Control 52.739935
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8236933
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7751432
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7573234
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7431334
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7046532
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7533834
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7464334
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7561733
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7308632